[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"connective-tissue-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:connective-tissue-disease":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,45,78,115,145,188,210],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100629632","heart-institute-biobank--registry-for-adult-congenital-heart-disease-and-related-disorders-100629632",false,"NCT07477197","Heart Institute Biobank & Registry for Adult Congenital Heart Disease and Related Disorders","HIBR-ACHD","Inclusion Criteria:\n\n1. Any person ≥ 16 years-old suspected of having or diagnosed with congenital heart disease (CHD), other cardiovascular disease (CVD), pulmonary hypertension, connective tissue disease, or genetic syndrome\u002Fdiagnosis.\n2. Additionally, a cohort (Control group A) of control subjects will be enrolled, again ≥16 years-old, self-reported non-smokers without a known history of diabetes mellitus, myocardial infarction, stroke, heart failure, or chronic kidney disease. These controls will be either:\n\n   1. A family member or other person accompanying a patient to a clinical encounter; or,\n   2. A volunteer recruited via an advertisement; or,\n   3. Another person who volunteers to enroll in HIBR-ACHD.\n3. A cohort (Control group B) of comparison subjects who do not have CHD, but have a diagnosis of heart failure or pulmonary hypertension.\n\nExclusion Criteria:\n\n* Unable to provide informed consent\u002Fassent personally or via a legal guardian.\n* Considered unsafe to collect the biospecimen determined by either a clinical provider or an HIBR-ACHD investigator.\n* Overnight hospitalization for non-obstetric reason with discharge in the prior 30 days.",true,"ALL","16 Years",{"count":20,"type":21},5000,"ESTIMATED","10 Years","OBSERVATIONAL","A repository of biospecimens and detailed phenotypic information collected longitudinally from adults with congenital heart disease and related conditions, with an aim to facilitate future research on biologic mechanisms of underlying disease, compensation and deterioration; biologic correlates of patient experience and functional status; associations between clinical characteristics and various biomarkers; and predictors of clinical outcomes.",[26,27,28,29],"Adult Congenital Heart Disease","Pulmonary Hypertension","Connective Tissue Disease","Other Cardiovascular Conditions",[31,26],"ACHD","RECRUITING","2026-03-13",{"date":35,"type":36},"2026-03-17","ACTUAL",{"date":38,"type":36},"2021-07-01",{"date":40,"type":21},"2050-01-01",{"name":42,"class":43},"Children's Hospital Medical Center, Cincinnati","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":65,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100605430","ganglion-resection-effectiveness-trial-100605430","NCT07162415","Ganglion Resection Effectiveness Trial","GangLion Resection Effectiveness Trial (GangLion): a Multicentre, Randomized, Superiority Trial","GangLion","Inclusion Criteria:\n\n* wrist pain located in the ganglion area\n* diagnosis of ganglion of the wrist, based on clinical examination or imaging findings\n* age over 18 years\n* ability to fill out the Finnish or English version of the questionnaires\n\nExclusion Criteria:\n\n* pregnant or breast feeding\n* other known wrist pathology that likely explains the pain\n* previous surgical treatments of the wrist\n* wrist ganglion presumed to be related to a work injury","18 Years",{"count":55,"type":21},220,"INTERVENTIONAL",[58],"NA","The goal of this clinical trial is to learn if surgery helps with wrist ganglions in adults. The main question it aims to answer is:\n\n* Does surgery result in better patient-reported outcomes and satisfaction over a 6-months follow-up period?\n\nResearchers will compare surgery to conservative treatment (self-administered exercises and use of the hand as tolerated) to see if surgery provides superior outcomes.\n\nParticipants will:\n\n* Be randomly assigned to receive either surgery or conservative treatment\n* Complete questionnaires about wrist pain, function, quality of life, satisfaction, and recovery at 3, 6, and 12 months",[61,62,63,28,64],"Wrist Ganglion","Ganglion","Ganglion Cyst","Mucinoses",[66,67],"ganglion","wrist","2026-01-19",{"date":70,"type":36},"2026-01-21",{"date":72,"type":36},"2026-01-13",{"date":74,"type":21},"2035-12",{"name":76,"class":43},"Tampere University Hospital",4,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":86,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":56,"phases":89,"briefSummary":91,"conditions":92,"keywords":102,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":88},"100586616","phase-3-a-study-to-learn-about-the-safety-and-efficacy-of-the-drug-oleogel-s10-in-japanese-patients-with-epidermolysis-bullosa-100586616","NCT06917690","A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa","Multi-centeR, Open-label Study to EValuate the Safety, Efficacy, and Pharmacokinetics of FIlsuVEz (Oleogel-S10) in Japanese Subjects With Epidermolysis Bullosa (REVIVE)","REVIVE","Inclusion Criteria:\n\n1. Male or female aged ≥ 21 days\n2. Confirmed diagnosis of either JEB or DEB\n3. Both biological parents and all 4 grandparents of Japanese descent\n4. At least 3 EB wounds that meet the following criteria at the time of enrollment:\n\n   * All are located outside of the anogenital region\n   * All are distinguishable from any other wounds on the subject's body (separated by a minimum of 5 cm)\n   * At least one has been present for a minimum of 21 days but less than 9 months AND is 10 cm2 to 50 cm2 in size\n   * At least two have been present for a minimum of 21 days but less than 9 months AND\u002FOR are 10 cm2 to 50 cm2 in size\n5. A female subject must meet one of the following criteria:\n\n   * If of childbearing potential, she must:\n\n     1. Have a negative pregnancy test result at Screening and Baseline Visits, AND\n     2. Agree to use one of the following highly reliable methods of contraception from the day of the informed consent signature until the day after the last Oleogel- S10 application. The following methods are acceptable:\n\n        * Placement of an intrauterine device (IUD) or intrauterine releasing system (IUS)\n        * Combined (both estrogen and progestogen) hormonal contraception (oral) associated with inhibition of ovulation, supplemented with a barrier method (preferably male condom)\n        * Bilateral tubal occlusion\n        * Sexual abstinence, defined as refraining from heterosexual intercourse during the entire study period\n        * Partner vasectomy, provided that the partner is the sole sexual partner and has received medical verification of the surgical success\n   * Be of non-childbearing potential, defined as one of the following:\n\n     * Pre-menarche, OR\n     * Post-menopausal (12 consecutive months of amenorrhea without an alternative medical cause), OR\n     * Permanently sterile following hysterectomy, bilateral salpingectomy, or bilateral oophorectomy (supporting evidence required)\n6. Subject and\u002For subject's legal representative has been informed about the study, has read and understood the information provided, and has given written informed consent\n7. Subject and\u002For subject's legal representative is able and willing to follow all study procedures and instructions\n\nExclusion Criteria:\n\n1. Hypersensitivity to Oleogel-S10 or any of its excipients\n2. Diagnosis of EB subtypes simplex or Kindler EB\n3. Receipt of systemic antibiotics for wound-related infections within 7 days prior to enrollment\n4. Receipt of systemic or topical (on EB wounds) steroids within 30 days prior to enrollment Exceptions: Inhaled, ophthalmic, or mucosal applications, such as budesonide suspension for esophageal strictures\n5. Receipt of immunosuppressive therapy or cytotoxic chemotherapy within 60 days prior to enrollment Note: Dupilumab to manage pruritis is allowed if the subject has been on a stable dose for more than 3 months prior to baseline\n6. Receipt of systemic gene therapy for the treatment of inherited EB\n7. Receipt of short-acting stem cell therapy (infusion of Muse cells, allogeneic adipocyte-derived MSC sheet (topically applied), TEMCELL (allogeneic MSCs, subcutaneous injection)) within 6 months prior to study enrollment\n8. Receipt of topical gene therapy for the treatment of inherited EB (e.g., beremagene geperpavec) within 3 months prior to enrollment\n9. Receipt of a JACE® skin graft on any of the target wounds\n10. Current and\u002For former malignancy, including skin malignancies such as basal cell carcinoma and squamous cell carcinoma\n11. Females: Pregnant or lactating, or of childbearing potential with a fertile male partner and unwilling to use a highly reliable method of contraception from the informed consent signature until study participation ends\n12. Enrollment in any other interventional study or treated with any other investigational drug for any disease within 4 weeks prior to enrollment\n13. Presence of any factor in the subject and\u002For legal representative that could interfere with study compliance, such as the ability to attend the scheduled study visits or to properly manage the dressing changes at home","21 Days",{"count":88,"type":21},6,[90],"PHASE3","The goal of this clinical trial is to learn if Oleogel-S10 gel works to treat skin wounds from two types of inherited epidermolysis bullosa (EB): junctional EB (JEB) or dystrophic EB (DEB) in the Japanese population. Children and adults may participate. The trial also looks at the safety of Oleogel-S10 gel. The main questions it will answer are:\n\n* Does Oleogel-S10 gel close wounds from JEB or DEB within 45 days or reduce the size of the wounds?\n* Are there any medical problems when using Oleogel-S10 gel?\n* How much of the drug ends up in your blood?\n\nThe study has 2 parts. In Part 1, participants will:\n\n* Apply Oleogel-S10 gel to the EB wound dressings at least once every 4 days for 45 days.\n* Visit the clinic once every 2 weeks for checkups and tests. If participants complete Part 1, they may participate in Part 2 if they choose to. In Part 2, participants will continue to receive Oleogel-S10 gel until the product is available to buy in Japan or until the trial is stopped by the company.",[93,94,95,96,97,28,98,99,100,101],"Epidermolysis Bullosa","Junctional Epidermolysis Bullosa","Epidermolysis Bullosa, Dystrophic","Epidermolysis Bullosa, Junctional","Skin Abnormalities","Collagen Diseases","Skin Diseases","Genetic Diseases, Inborn","Congenital Abnormalities",[103,104],"Filsuvez","Birch Bark extract","2025-12-18",{"date":107,"type":36},"2025-12-22",{"date":109,"type":36},"2025-04-18",{"date":111,"type":21},"2029-09",{"name":113,"class":114},"Chiesi Farmaceutici S.p.A.","INDUSTRY",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":56,"phases":125,"briefSummary":126,"conditions":127,"keywords":132,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":44},"100594692","personalized-outreach-for-equitable-treatment-in-rheumatology-100594692","NCT07022756","Personalized Outreach for Equitable Treatment in Rheumatology","Personalized Outreach for Equitable Treatment in Rheumatology: A Randomized Controlled Trial of Patient Outreach and Honoraria in an Inner City Rheumatology Clinic","POET-Rheum","Inclusion Criteria:\n\n* Have a diagnosis of inflammatory arthritis secondary to an autoimmune rheumatic disease\n* Be attached to one of the Vancouver Coastal Health Community Health Centres for primary care\n* Be willing to attend in-person appointments at Pender Community Health Centre\n* Be at least 18 years of age and capable of consenting to participation\n* Be able to receive medical care in English.\n\nExclusion Criteria:\n\n* Have cognitive impairment or an untreated psychiatric condition that would severely impair ability to engage with outreach or treatment\n* Have no reasonably reliable method of contact (phone, email, social media, etc.)",{"count":124,"type":21},20,[58],"The primary goal of this study is to determine whether providing patient honoraria and\u002For outreach services can improve the attendance rate of appointments at an inner city rheumatology clinic in Vancouver, British Columbia.\n\nThe main question it aims to answer are:\n\n* Does providing a financial honorarium ($20 for each follow-up appointment with completed bloodwork) improve attendance rate at an inner city rheumatology clinic?\n* Does providing a personalized outreach service for rheumatic diseases improve attendance rate at an inner city rheumatology clinic?\n\nThe researchers will compare providing patient honoraria to providing both honoraria and outreach services, and compare each of these to the regular appointment schedule without honoraria or outreach.\n\nParticipants will:\n\n* Undergo randomization to receive honoraria or honoraria and outreach services together\n* Complete surveys about their health and understanding of their rheumatic disease at baseline, 3-month, and 6-month intervals\n* Visit the clinic every month for check-ups and monitoring bloodwork if they are started on immunosuppressants for their condition",[128,129,130,131,28],"Rheumatic Diseases","Inflammatory Arthritis","Rheumatoid Arthritis (RA)","Psoriatic Arthritis (PsA)",[133,129,134],"Rheumatology","Inner City Health","NOT_YET_RECRUITING","2025-07-01",{"date":138,"type":36},"2025-07-04",{"date":140,"type":21},"2025-07-02",{"date":142,"type":21},"2026-06",{"name":144,"class":43},"University of British Columbia",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":16,"sex":153,"minAge":154,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":157,"conditions":158,"keywords":169,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":44},"100569575","aylo---autoimmunity-and-loss-of-y-100569575","NCT06696027","AYLo - AutoimmunitY and Loss of y","Investigating the Role of Hematopoietic Mutations and Mosaic Mutation in the Y Chromosome in Autoimmune Rheumatologic Diseases","AYLo","Inclusion Criteria:\n\n* Male\n* \\> 50 years\n* Diagnosis of arthritis (RA, PsA), collagen diseases (SLE, systemic sclerosis, Sjögren's syndrome, mixed connective tissue diseases), vasculitis (eGPA, GPA, MPA, IgG4-related disease, GCA, PMR), sarcoidosis, COPD, ILD or asthma bronchiale confirmed by the treating physician.\n\nExclusion Criteria:\n\n* Female\n* \\\u003C 50 years\n\nInclusion Criteria (Healthy controls):\n\n* Male\n* \\> 50 years\n\nExclusion Criteria (Healthy controls):\n\n* Female\n* \\\u003C 50 years\n* autoimmune, rheumatological diease\n* pulmonary precondition","MALE","50 Years",{"count":156,"type":21},500,"The AYLo study (AutoimmunitY and Loss of y - Investigating the Role of Hematopoietic Mutations and Mosaic Mutation in the Y Chromosome in Autoimmune Rheumatologic Diseases) aims to systematically investigate hematopoietic mutations, such as hematopoietic (mosaic) loss of the Y chromosome (mLOY), focusing on their underlying causes, pathophysiological significance, patterns of manifestation, and impact on disease progression in autoimmune, rheumatologic disorders. This research seeks to bridge existing knowledge gaps by exploring how such mutations influence immune homeostasis, cellular function, and susceptibility to inflammation-driven pathologies.\n\nThrough the integration of advanced immunological profiling, the study aspires to uncover key mechanisms that drive the initiation, progression, and complications of autoimmune rheumatic diseases. These analyses will combine single nucleotide polymorphisms (SNP) arrays, multiplex assays, transcriptomics, and flow cytometry staining of peripheral blood mononuclear cells to delineate the interplay between hematopoietic mutations and immune dysregulation.\n\nA further objective is the development of a multimodal framework for disease-specific characterization, enabling precise mapping of mutation-driven phenotypes across diverse autoimmune conditions. This framework will incorporate clinical, molecular, and imaging data.\n\nAdditionally, the AYLo study aims to explore the potential role of mLOY and other hematopoietic mutations as biomarkers for disease stratification, prognosis, and therapeutic response. The findings may open avenues for personalized treatment approaches, leveraging the molecular insights to inform targeted interventions and improve patient outcomes in autoimmune rheumatic disorders.\n\nBy integrating translational and basic science approaches, this study has the potential to redefine current paradigms in autoimmune disease research and therapy.",[159,160,161,162,163,130,131,28,164,165,166,167,168],"Giant Cell Arteritis (GCA)","Polymyalgia Rheumatica (PMR)","ANCA Associated Vasculitis (AAV)","Idiopathic Inflammatory Myopathies","IgG4-Related Diseases","Sarcoidosis","Interstitial Lung Disease Due to Systemic Disease (Disorder)","Interstitial Lung Disease (ILD)","Asthma Bronchiale","COPD",[170,171,172,173,174,175,162,163,176,177,28,164,178],"Autoimmune Diseases","Vasculitis","Large Vessel Vasculitis","Giant Cell Arteritis","Polymyalgia Rheumatica","ANCA Associated Vasculitis","Rheumatoid Arthritis","Psoriatic Arthritis","Interstitial Lung Disease","2025-04-07",{"date":181,"type":36},"2025-04-10",{"date":183,"type":36},"2024-11-15",{"date":185,"type":21},"2026-07",{"name":187,"class":43},"University of Bonn",{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":198,"conditions":199,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":44},"100576016","characterization-of-bamboo-and-other-vocal-cord-lesions-responsible-for-dysphonia-in-patients-with-systemic-autoimmune-diseases-bamboo-100576016","NCT06779799","Characterization of \"Bamboo\" and Other Vocal Cord Lesions Responsible for Dysphonia in Patients With Systemic Autoimmune Diseases (BAMBOO)","Characterization of \"Bamboo\" and Other Vocal Cord Lesions Responsible for Dysphonia in Patients With Systemic Autoimmune Diseases.","BAMBOO","Inclusion Criteria:\n\n* Patients aged 18 years or older\n* With a systemic autoimmune disease : rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, primary Sjogren disease, sarcoidosis, vasculitis, myositis, Still disease, Sharp syndrome.\n* Suffering from dysphonia.\n* With a cord vocal\u002Flaryngeal lesion highlighted.\n\nExclusion Criteria:\n\n* Patients under the age of 18 years\n* Dysphonia due to a cord vocal palsy related to a neurological condition or malignancy\n* History of cervical radiation\n* History of oro-tracheal intubation\n* Laryngeal cancer\n* Participation deny\n* Impossibility of consent\n* Patients with legal protection",{"count":197,"type":21},150,"The goal of this multicenter retrospective observational study is to provide an inventory of the specific and non specific cord vocal lesions that can cause dysphonia in patients with systemic autoimmune diseases. The main question it aims to answer is:\n\n* What are the main cord vocal lesions responsible for dysphonia in patients with a systemic autoimmune disease?\n* Is there a diagnosis delay regarding those lesions?\n* How are those lesions managed? Participants suffering from dysphonia in a context of a systemic autoimmune disease will be identified, with a review of their medical record.",[200,28,171],"Dysphonia","2025-01-13",{"date":203,"type":36},"2025-01-17",{"date":205,"type":36},"2024-12-01",{"date":207,"type":21},"2025-05-31",{"name":209,"class":43},"University Hospital, Brest",{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":217,"targetDuration":4,"studyType":56,"phases":219,"briefSummary":221,"conditions":222,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":44},"100554449","phase-4-efficacy-and-safety-of-prophylactic-treatment-for-pneumocystis-jirovecii-pneumonia-in-patients-with-autoimmune-inflammatory-rheumatic-disease-100554449","NCT06499233","Efficacy and Safety of Prophylactic Treatment for Pneumocystis Jirovecii Pneumonia in Patients With Autoimmune Inflammatory Rheumatic Disease","Efficacy and Safety of Prophylactic Treatment for Pneumocystis Jirovecii Pneumonia (PJP) in Patients With Autoimmune Inflammatory Rheumatic Disease (AIIRD)","Inclusion Criteria:\n\n1. The patient was diagnosed with AIIRD according to the International Classification of Diseases and had received steroids or immunosuppressive therapy;\n2. The patient had not received standard PJP treatment before enrollment, including the first-line treatment drug TMP\u002FSMZ, or other second-line treatment drugs (including Pentamidine, Atorvastatin, Caspofungin, etc.);\n3. The patient was at least 18 years old at the time of enrollment;\n\nExclusion Criteria:\n\n1. Serious health problems or diseases, including (but not limited to) the following: severe liver damage (ALT, AST elevated above normal value by more than 5 times), severe renal insufficiency (GFR \\\u003C 30mL\u002Fmin or Scr \\> 445umol\u002FL), severe myelosuppression (Hb \\\u003C 65g\u002FL, PLT \\\u003C 25×10\\^9\u002FL or neutrophils \\\u003C 0.5×10\\^9\u002FL);\n2. Screening test indicates infection with human immunodeficiency virus (HIV), history of lymphomatous hyperplasia of the lymphatic tissue or any malignant tumor of any organ system within the past 5 years, or history of organ transplantation;\n3. Participants with a history of allergy to sulfonamide drugs, megaloblastic anemia due to folate deficiency;\n4. Pregnant and lactating women;\n5. Any medical or psychological condition that the investigator believes would interfere with the participant's ability to comply with the protocol or complete the study;\n6. Patients who refuse to comply with the requirements of this study and complete the study;\n7. Any other situation that the investigator considers unsuitable for participation in the study (for reasons including but not limited to management reasons).",{"count":218,"type":21},800,[220],"PHASE4","This is an open-labeled, prospective clinical study aims at collecting and analyzing baseline characteristics of autoimmune inflammatory rheumatic disease (AIIRD) patients receiving sulfanilamide for preventive purposes, as well as subsequent follow-up data, in order to assess the efficacy and safety of the medication. Additionally, through a stratified analysis of risk factors, the investigators aim to identify the AIIRD population that would benefit most from preventive medication based on a favorable benefit-risk ratio.",[223,224,170,28,225],"Pneumonia, Pneumocystis","Autoimmune Inflammatory Rheumatic Disease","Prevention","2024-09-27",{"date":228,"type":36},"2024-10-01",{"date":230,"type":36},"2024-07-20",{"date":232,"type":21},"2026-12-31",{"name":234,"class":43},"Tongji Hospital"]